Patents Examined by Ruixiang Li
  • Patent number: 11041012
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: June 22, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell
  • Patent number: 11034940
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 15, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Patent number: 11026997
    Abstract: The present invention provides, among other things, methods of treating post-cardiac injury syndrome (PCIS) or pericarditis, comprising a step of administering to a subject in need of treatment an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more signs and symptoms of pericarditis relative to a control.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: June 8, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eben Tessari, John Paolini
  • Patent number: 11028145
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: June 8, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay, Gang Li, Yossi Dagon, John Knopf
  • Patent number: 11021728
    Abstract: Herein is reported a method for the production of an immunoglobulin comprising the following steps: a) providing a eukaryotic cell comprising a nucleic acid encoding the immunoglobulin, b) cultivating the eukaryotic cell in a cultivation medium wherein the amount of glucose available in the cultivation medium per time unit is kept constant and limited to less than 80% of the amount that could maximally be utilized by the cells in the cultivation medium per time unit, and c) recovering the immunoglobulin from the culture.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: June 1, 2021
    Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Reinhard Franze, Chikashi Hirashima, Thomas Link, Yoshinori Takagi, Shinya Takuma, Yuriko Tsuda
  • Patent number: 11014973
    Abstract: Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g., EGFRvIII-expressing cells that also express interferon receptors) and that induce anti-proliferative effects, and related compositions and methods for the treatment of cancer.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 25, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Jeffrey Charles Way, Avram Lev Robinson-Mosher
  • Patent number: 11008378
    Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: May 18, 2021
    Assignee: University of Connecticut
    Inventors: Leo Lefrancois, Thomas A. Stoklasek
  • Patent number: 10995143
    Abstract: The present invention relates to the medical use of antibodies against the FGF receptor 4 (FGFR4) combined with Sorafenib, in particular for the prevention or treatment of hyperproliferative diseases associated with FGFR expression, overexpression or hyperactivity.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: May 4, 2021
    Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company Limited
    Inventors: Reimar Abraham, Keisuke Fukuchi
  • Patent number: 10994011
    Abstract: Provided is a stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants, or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 4, 2021
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Megumi Ikeda, Akinori Chikushi
  • Patent number: 10981978
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: April 20, 2021
    Assignee: CORIXA CORPORATION
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • Patent number: 10981999
    Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 20, 2021
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Patent number: 10975151
    Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: April 13, 2021
    Inventors: Thomas Hofer, Changhua Ji, Ekkehard Moessner, Pablo Umana
  • Patent number: 10976300
    Abstract: Provided herein relate to modified or mutant forms of cytolysin A (ClyA) and compositions comprising the same. In particular, the modified or mutant forms of ClyA permits efficient capture and/or translocation of a target negative-charged molecule or polymer through the modified or mutant ClyA nanopores at low or physiological ionic strengths. Thus, methods for using the modified or mutant forms of ClyA and compositions, for example, for characterizing a target negatively-charged analyte, e.g., a target polynucleotide, are also provided.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: April 13, 2021
    Assignee: Katholieke Universiteit Leuven
    Inventors: Giovanni Maglia, Lorenzo Franceschini, Tine Brouns, Andrew John Heron, Lakmal Nishantha Jayasinghe, Elizabeth Jayne Wallace
  • Patent number: 10976311
    Abstract: Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: April 13, 2021
    Assignee: Katholieke Universiteit Leuven
    Inventors: Giovanni Maglia, Mikhael Soskine
  • Patent number: 10968275
    Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: April 6, 2021
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Ashwini Balakrishnan, Benjamin G. Hoffstrom, Julie Randolph-Habecker, Stanley R. Riddell
  • Patent number: 10962538
    Abstract: The current invention is methods and assays for detecting and/or measuring the modification, i.e., activation or inhibition, of a receptor of interest, without the need to modify the receptor with a label or a tag. The invention uses proteins that move, translocate, are recruited and/or bind to the receptor of interest when the receptor is modified, and proteins in proximity to and/or in the same compartment as the receptor of interest. The proteins are attached or linked to polypeptides that result from the unique cleavage of a modified Oplophorus luciferase. When the proteins are in proximity allowing the unique polypeptides to recombine, a luminescent signal is generated. The invention also includes vector encoding these proteins, cells expressing these proteins, compositions, system and kits.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 30, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jonathan A Javitch, Maria Hauge Pedersen
  • Patent number: 10940213
    Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 9, 2021
    Assignees: Rigshospitalet, University of Copenhagen
    Inventors: Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
  • Patent number: 10927174
    Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: February 23, 2021
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Ashwini Balakrishnan, Benjamin G. Hoffstrom, Julie Randolph-Habecker, Stanley R. Riddell
  • Patent number: 10906957
    Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: February 2, 2021
    Assignee: EpicentRx, Inc.
    Inventors: Christopher Larson, Tony R. Reid, Bryan T. Oronsky
  • Patent number: 10906971
    Abstract: Monoclonal antibody that specifically binds the interleukin 1 receptor type 1 (IL-1RAcP), or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: February 2, 2021
    Assignee: SANOFI BIOTECHNOLOGY SAS
    Inventors: Stephan Fischer, Michael Brandt